pitavastatin

P=N/A, N=10000, Recruiting, JW Pharmaceutical

Notably, pitavastatin calcium synergized with the ferroptosis inducer RSL3 to enhance ferroptotic activity and suppress HNSCC progression. These findings delineate a TRAPPC4-FOS-TRIM55-GPX4 signaling axis that drives ferroptosis resistance and tumor progression and highlight TRAPPC4 as a promising therapeutic target for ferroptosis-based intervention in HNSCC.

P1, N=40, Recruiting, Hoffmann-La Roche

P1, N=32, Active, not recruiting, Genentech Inc. | Recruiting --> Active, not recruiting

P2, N=150, Recruiting, Lomonosov Moscow State University Medical Research and Educational Center

P1, N=40, Recruiting, Hoffmann-La Roche | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026

P=N/A, N=6927, Completed, JW Pharmaceutical

P4, N=88, Active, not recruiting, JW Pharmaceutical

P1, N=32, Recruiting, Genentech Inc.

Targeting this pathway with clinically approved statins (atorvastatin, pitavastatin, simvastatin) synergized with PT2385 to suppress CRC cell growth, reduce colony formation, and enhance cell death...These effects are fully reversed by the ferroptosis inhibitor liproxstatin-1...In vivo, co-administration of PT2385 and atorvastatin significantly reduced tumor growth and increased ferroptotic cell death in xenografts, confirming the mechanistic link. Collectively, these findings uncover a metabolic vulnerability of CRC to dual HIF-2α and cholesterol biosynthesis inhibition, supporting a clinically actionable strategy that leverages safe, FDA-approved statins to potentiate HIF-2α-targeted therapy.

P=N/A, N=22, Not yet recruiting, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital

P3, N=300, Active, not recruiting, Kirby Institute | Recruiting --> Active, not recruiting